A modular allogeneic CAR-NK cell therapy that targets cancer and its tumor microenvironment

PRINCIPLE INVESTIGATOR:
Dr. Dimitrios Laurin Wagner, Jonas Kath, Clemens Franke
Charité

SUMMARY

One of the most promising immuno-therapies against cancer is the adoptive cell transfer of genetically modified T cells. However, so far, attempts have been unsuccessful in some cancers, like acute myeloid leukemia or most solid tumors. This project aims to develop a modular allogeneic CAR-NK cell product for improved treatment of cancer, alone or as co-treatment with a monoclonal antibody.

PROJECT GOALS

- Development of a modular allogeneic CAR-NK cell product
- Preclinical characterization in vitro

LONG-TERM GOALS

- Perform phase I / II clinical trial
- License to Biotech/Pharma or Startup foundation